Delayed graft function and primary non-function are serious complications following transplantation of kidneys derived from deceased brain dead (DBD) donors. α-melanocyte stimulating hormone (α-MSH) is a pleiotropic neuropeptide and its renoprotective effects have been demonstrated in models of acute kidney injury. We hypothesized that α-MSH treatment of the recipient improves early graft function and reduces inflammation following DBD kidney transplantation. Eight Danish landrace pigs served as DBD donors. After four hours of brain death both kidneys were removed and stored for 18 hours at 4°C in Custodiol preservation solution. Sixteen recipients were randomized in a paired design into two treatment groups, transplanted simultaneously. α-MSH or a vehicle was administered at start of surgery, during reperfusion and two hours post-reperfusion. The recipients were observed for ten hours following reperfusion. Blood, urine and kidney tissue samples were collected during and at the end of follow-up. α-MSH treatment reduced urine flow and impaired recovery of glomerular filtration rate (GFR) compared to controls. After each dose of α-MSH, a trend towards reduced mean arterial blood pressure and increased heart rate was observed. α-MSH did not affect expression of inflammatory markers. Surprisingly, α-MSH impaired recovery of renal function in the first ten hours following DBD kidney transplantation possibly due to hemodynamic changes. Thus, in a porcine experimental model α-MSH did not reduce renal inflammation and did not improve short-term graft function following DBD kidney transplantation.
References
[1]
Rahmel A (2012) Annual report 2012. Eurotransplant international foundation.
[2]
Snoeijs MG, Winkens B, Heemskerk MB, Hoitsma AJ, Christiaans MH, et al. (2010) Kidney transplantation from donors after cardiac death: A 25-year experience. Transplantation 90: 1106–1112. doi: 10.1097/tp.0b013e3181f83b0b
[3]
Barlow AD, Metcalfe MS, Johari Y, Elwell R, Veitch PS, et al. (2009) Case-matched comparison of long-term results of non-heart beating and heart-beating donor renal transplants. Br J Surg 96: 685–691. doi: 10.1002/bjs.6607
[4]
Wadei HM, Heckman MG, Rawal B, Taner CB, Farahat W, et al. (2013) Comparison of kidney function between donation after cardiac death and donation after brain death kidney transplantation. Transplantation 96: 274–281. doi: 10.1097/tp.0b013e31829807d1
[5]
de Vries DK, Lindeman JH, Ringers J, Reinders ME, Rabelink TJ, et al. (2011) Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant 11: 1064–1070. doi: 10.1111/j.1600-6143.2011.03466.x
[6]
Nijboer WN, Schuurs TA, van der Hoeven JA, Fekken S, Wiersema-Buist J, et al. (2004) Effect of brain death on gene expression and tissue activation in human donor kidneys. Transplantation 78: 978–986. doi: 10.1097/01.tp.0000135565.49535.60
[7]
van Werkhoven MB, Damman J, van Dijk MC, Daha MR, de Jong IJ, et al. (2013) Complement mediated renal inflammation induced by donor brain death: Role of renal C5a-C5aR interaction. Am J Transplant 13: 875–882. doi: 10.1111/ajt.12130
[8]
van der Hoeven JA, Molema G, Ter Horst GJ, Freund RL, Wiersema J, et al. (2003) Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. Kidney Int 64: 1874–1882. doi: 10.1046/j.1523-1755.2003.00272.x
[9]
Watts RP, Thom O, Fraser JF (2013) Inflammatory signalling associated with brain dead organ donation: From brain injury to brain stem death and posttransplant ischaemia reperfusion injury. J Transplant 2013: 521369. doi: 10.1155/2013/521369
[10]
Lee SY, Jo SK, Cho WY, Kim HK, Won NH (2004) The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine A nephrotoxicity. Transplantation 78: 1756–1764. doi: 10.1097/01.tp.0000144332.44435.ab
[11]
Li C, Shi Y, Wang W, Sardeli C, Kwon TH, et al. (2006) Alpha-MSH prevents impairment in renal function and dysregulation of AQPs and na-K-ATPase in rats with bilateral ureteral obstruction. Am J Physiol Renal Physiol 290: F384–96. doi: 10.1152/ajprenal.00282.2004
[12]
Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, et al. (1997) Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 99: 1165–1172. doi: 10.1172/jci119272
[13]
Chiao H, Kohda Y, McLeroy P, Craig L, Linas S, et al. (1998) Alpha-melanocyte-stimulating hormone inhibits renal injury in the absence of neutrophils. Kidney Int 54: 765–774. doi: 10.1046/j.1523-1755.1998.00075.x
[14]
Kwon TH, Frokiaer J, Fernandez-Llama P, Knepper MA, Nielsen S (1999) Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: Prevention by alpha-MSH. Am J Physiol 277: F413–27.
[15]
Jo SK, Yun SY, Chang KH, Cha DR, Cho WY, et al. (2001) Alpha-MSH decreases apoptosis in ischaemic acute renal failure in rats: Possible mechanism of this beneficial effect. Nephrol Dial Transplant 16: 1583–1591. doi: 10.1093/ndt/16.8.1583
[16]
Gong H, Wang W, Kwon TH, Jonassen T, Li C, et al. (2004) EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 66: 683–695. doi: 10.1111/j.1523-1755.2004.00791.x
[17]
Simmons MN, Subramanian V, Crouzet S, Haber GP, Colombo JR Jr, et al. (2010) Alpha-melanocyte stimulating hormone analogue AP214 protects against ischemia induced acute kidney injury in a porcine surgical model. J Urol 183: 1625–1629. doi: 10.1016/j.juro.2009.12.007
[18]
Barklin A, Larsson A, Vestergaard C, Koefoed-Nielsen J, Bach A, et al. (2008) Does brain death induce a pro-inflammatory response at the organ level in a porcine model? Acta Anaesthesiol Scand 52: 621–627. doi: 10.1111/j.1399-6576.2008.01607.x
[19]
Soendergaard P, Krogstrup NV, Secher NG, Ravlo K, Keller AK, et al. (2012) Improved GFR and renal plasma perfusion following remote ischaemic conditioning in a porcine kidney transplantation model. Transpl Int 25: 1002–1012. doi: 10.1111/j.1432-2277.2012.01522.x
[20]
Rinne P, Tikka S, Makela S, Streng T, Savontaus E (2012) Hemodynamic actions and mechanisms of systemically administered alpha-MSH analogs in mice. Peptides 38: 150–158. doi: 10.1016/j.peptides.2012.09.004
[21]
Ni XP, Butler AA, Cone RD, Humphreys MH (2006) Central receptors mediating the cardiovascular actions of melanocyte stimulating hormones. J Hypertens 24: 2239–2246. doi: 10.1097/01.hjh.0000249702.49854.fa
[22]
van Bergen P, Kleijne JA, De Wildt DJ, Versteeg DH (1997) Different cardiovascular profiles of three melanocortins in conscious rats; evidence for antagonism between gamma 2-MSH and ACTH-(1-24). Br J Pharmacol 120: 1561–1567. doi: 10.1038/sj.bjp.0701065
[23]
Dyster-Aas HK, Krakau CE (1965) General effects of alpha-melanocyte stimulating hormone in the rabbit. Acta Endocrinol (Copenh) 48: 609–618. doi: 10.1530/acta.0.0480609
[24]
Llanos AJ, Seron-Ferre M, Ramachandran J, Creasy RK, Heymann MA, et al. (1983) Cardiovascular responses to alpha-melanocyte stimulating hormone during the perinatal period in sheep. Pediatr Res 17: 903–908. doi: 10.1203/00006450-198311000-00013
[25]
Rinne P, Nordlund W, Heinonen I, Penttinen AM, Saraste A, et al. (2013) Alpha-melanocyte-stimulating hormone regulates vascular NO availability and protects against endothelial dysfunction. Cardiovasc Res 97: 360–368. doi: 10.1093/cvr/cvs335
[26]
Lindskog A, Ebefors K, Johansson ME, Stefansson B, Granqvist A, et al. (2010) Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 21: 1290–1298. doi: 10.1681/asn.2009101025
[27]
Brewster UC, Setaro JF, Perazella MA (2003) The renin-angiotensin-aldosterone system: Cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326: 15–24. doi: 10.1097/00000441-200307000-00003
[28]
Catania A, Gatti S, Colombo G, Lipton JM (2004) Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56: 1–29. doi: 10.1124/pr.56.1.1
[29]
Kohda Y, Chiao H, Star RA (1998) Alpha-melanocyte-stimulating hormone and acute renal failure. Curr Opin Nephrol Hypertens 7: 413–417. doi: 10.1097/00041552-199807000-00011
[30]
Brzoska T, Luger TA, Maaser C, Abels C, Bohm M (2008) Alpha-melanocyte-stimulating hormone and related tripeptides: Biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 29: 581–602. doi: 10.1210/er.2007-0027
[31]
Spaccapelo L, Bitto A, Galantucci M, Ottani A, Irrera N, et al. (2011) Melanocortin MC(4) receptor agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia. Eur J Pharmacol 670: 479–486. doi: 10.1016/j.ejphar.2011.09.015
[32]
Lee YS, Park JJ, Chung KY (2008) Change of melanocortin receptor expression in rat kidney ischemia-reperfusion injury. Transplant Proc 40: 2142–2144. doi: 10.1016/j.transproceed.2008.07.101
[33]
Hussein AA, El-Dken ZH, Barakat N, Abol-Enein H (2012) Renal ischaemia/reperfusion injury: Possible role of aquaporins. Acta Physiol (Oxf) 204: 308–316. doi: 10.1111/j.1748-1716.2011.02372.x
[34]
Jensen AM, Li C, Praetorius HA, Norregaard R, Frische S, et al. (2006) Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction. Am J Physiol Renal Physiol 291: F1021–32. doi: 10.1152/ajprenal.00387.2005
